InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: cheynew post# 202749

Thursday, 01/15/2015 11:07:34 AM

Thursday, January 15, 2015 11:07:34 AM

Post# of 346056
CSM certainly talked the talk about them being advanced in labeling and last minute changes and CEO Gerald Finken even filing for a patent for labeling controls. I can't find one other CEO of a CRO that files a patent for labeling controls and has the biggest labeling sabotage happen under his watch that he (Finken) was in total control of.

Peregrine took it on the chin and speaking up about what happened and what does Finken do? He goes off with another ex-CSM employee and now CEO of another CRO

If CSM is found at fault, every single one of the customers or clients that Finken has under the new company should be made aware but hold it, maybe he only takes on BMS jobs and they "understand" : )

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News